Oral SERD Camizestrant Prolongs PFS vs Fulvestrant in Breast Cancer

"The results of SERENA-2 support further development of camizestrant in ER-positive breast cancer."
MDedge News

source https://www.medscape.com/viewarticle/985507?src=rss

Comments

Post a Comment

Popular posts from this blog